{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:22:31Z","timestamp":1785518551101,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-026-00817-1","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:38:44Z","timestamp":1785515924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of SGLT-2 Inhibitors in Patients with Uncontrolled or Resistant Hypertension: A Pilot Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6176-4241","authenticated-orcid":false,"given":"Omer","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9163-3271","authenticated-orcid":false,"given":"Sun Hyeok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5005-1211","authenticated-orcid":false,"given":"Aditya","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1385-5176","authenticated-orcid":false,"given":"Nehal","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-8727","authenticated-orcid":false,"given":"Raissa Santos","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8623-2296","authenticated-orcid":false,"given":"Afthab Salam","family":"Kanniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0662-4828","authenticated-orcid":false,"given":"Basil","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2137-1615","authenticated-orcid":false,"given":"Ana-C\u0103t\u0103lina","family":"Dasc\u0103lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni J.","family":"Nanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-5509","authenticated-orcid":false,"given":"Laura Marcela","family":"Romero-Acero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9664-6046","authenticated-orcid":false,"given":"Michele","family":"Nanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"5","key":"817_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","volume":"102","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102(5):974\u201389. https:\/\/doi.org\/10.1016\/j.kint.2022.08.012.","journal-title":"Kidney Int"},{"issue":"10","key":"817_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887.","journal-title":"Circulation"},{"issue":"9","key":"817_CR3","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","volume":"76","author":"SR Das","year":"2020","unstructured":"Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, et al. Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2020;76(9):1117\u201345. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.037.","journal-title":"J Am Coll Cardiol"},{"key":"817_CR4","doi-asserted-by":"publisher","unstructured":"Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, Lo KB, Tuttle K, Vaduganathan M, Ventura H, McCullough PA; American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Lifestyle and Cardiometabolic Health. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation. 2020;142(17)\u2013e286. https:\/\/doi.org\/10.1161\/CIR.0000000000000920.","DOI":"10.1161\/CIR.0000000000000920"},{"key":"817_CR5","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK; ESC Scientific Document Group. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J. 2021;42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","DOI":"10.1093\/eurheartj\/ehab368"},{"issue":"18","key":"817_CR6","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"DW Jones","year":"2025","unstructured":"Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2025;86(18):1567\u2013678. https:\/\/doi.org\/10.1016\/j.jacc.2025.05.007.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"817_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/HCO.0000000000000865","volume":"36","author":"M Alqudsi","year":"2021","unstructured":"Alqudsi M, Velez JCQ, Navarrete J. Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Curr Opin Cardiol. 2021;36(4):420\u20138. https:\/\/doi.org\/10.1097\/HCO.0000000000000865.","journal-title":"Curr Opin Cardiol"},{"issue":"12","key":"817_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11906-023-01281-1","volume":"25","author":"B Beal","year":"2023","unstructured":"Beal B, Schutte AE, Neuen BL. Blood pressure effects of SGLT2 inhibitors: mechanisms and clinical evidence in different populations. Curr Hypertens Rep. 2023;25(12):429\u201335. https:\/\/doi.org\/10.1007\/s11906-023-01281-1.","journal-title":"Curr Hypertens Rep"},{"key":"817_CR9","doi-asserted-by":"publisher","unstructured":"B\u00f6hm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, Ferreira JP, Pocock SJ, Brueckmann M, Hauske SJ, Schueler E, Wanner C, Verma S, Zannad F, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators. Empagliflozin in Resistant Hypertension and Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Eur Heart J. 2025;46(14):1304\u20131317. https:\/\/doi.org\/10.1093\/eurheartj\/ehae938.","DOI":"10.1093\/eurheartj\/ehae938"},{"issue":"18","key":"817_CR10","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","volume":"139","author":"K Kario","year":"2019","unstructured":"Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2019;139(18):2089\u201397. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037076.","journal-title":"Circulation"},{"key":"817_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"817_CR12","unstructured":"RevMan (Review Manager) [Computer program]. Version 5.4.1. The Cochrane Collaboration; 2020. Available from: https:\/\/revman.cochrane.org."},{"key":"817_CR13","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Version 4.5.2 [Computer software]. Vienna: R Foundation for Statistical Computing; 2025. Available from: https:\/\/www.R-project.org\/."},{"key":"817_CR14","unstructured":"Rohatgi A. WebPlotDigitizer. Version 5.2 [Computer software]. Available from: https:\/\/automeris.io\/WebPlotDigitizer."},{"issue":"6","key":"817_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","volume":"68","author":"G Mancia","year":"2016","unstructured":"Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, et al. Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication. Hypertension. 2016;68(6):1355\u201364. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07703.","journal-title":"Hypertension"},{"key":"817_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ahj.2024.02.006","volume":"270","author":"HJL Heerspink","year":"2024","unstructured":"Heerspink HJL, Provenzano M, Vart P, Jongs N, Correa-Rotter R, Rossing P, et al. Dapagliflozin and blood pressure in patients with chronic kidney disease and albuminuria. Am Heart J. 2024;270:125\u201335. https:\/\/doi.org\/10.1016\/j.ahj.2024.02.006.","journal-title":"Am Heart J"},{"issue":"18","key":"817_CR17","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","volume":"143","author":"N Ye","year":"2021","unstructured":"Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, et al. Blood Pressure effects of Canagliflozin and clinical outcomes in type 2 Diabetes and chronic kidney disease: insights from the CREDENCE trial. Circulation. 2021;143(18):1735\u201349. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.048740.","journal-title":"Circulation"},{"issue":"16","key":"817_CR18","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1001\/jama.2026.1221","volume":"335","author":"M Azizi","year":"2026","unstructured":"Azizi M, Vongpatanasin W, Fisher NDL, Mahfoud F, Amar L, Kirtane AJ. Diagnosis and management of resistant hypertension: a review. JAMA. 2026;335(16):1428\u201339. https:\/\/doi.org\/10.1001\/jama.2026.1221.","journal-title":"JAMA"},{"issue":"6","key":"817_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1093\/ajh\/hpae020","volume":"37","author":"G Bakris","year":"2024","unstructured":"Bakris G, Chen C, Campbell AK, Ashton V, Haskell L, Singhal M. Real-world impact of blood pressure control in patients with apparent treatment-resistant or difficult-to-control hypertension and stages 3 and 4 chronic kidney disease. Am J Hypertens. 2024;37(6):438\u201346. https:\/\/doi.org\/10.1093\/ajh\/hpae020.","journal-title":"Am J Hypertens"},{"issue":"15","key":"817_CR20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-art review. J Am Coll Cardiol. 2018;72(15):1845\u201355. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.040.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"817_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","volume":"26","author":"E Ferrannini","year":"2017","unstructured":"Ferrannini E. Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26(1):27\u201338. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.011.","journal-title":"Cell Metab"},{"issue":"1","key":"817_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12933-022-01492-x","volume":"21","author":"CC van Ruiten","year":"2022","unstructured":"van Ruiten CC, Smits MM, Kok MD, Sern\u00e9 EH, van Raalte DH, Kramer MHH, et al. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovasc Diabetol. 2022;21(1):63. https:\/\/doi.org\/10.1186\/s12933-022-01492-x.","journal-title":"Cardiovasc Diabetol"},{"key":"817_CR23","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","volume":"13","author":"J Tang","year":"2022","unstructured":"Tang J, Ye L, Yan Q, Zhang X, Wang L. Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism. Front Pharmacol. 2022;13:800490. https:\/\/doi.org\/10.3389\/fphar.2022.800490.","journal-title":"Front Pharmacol"},{"issue":"16","key":"817_CR24","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.3390\/ijms22168786","volume":"22","author":"W Durante","year":"2021","unstructured":"Durante W, Behnammanesh G, Peyton KJ. Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling. Int J Mol Sci. 2021;22(16):8786. https:\/\/doi.org\/10.3390\/ijms22168786.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"817_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11\u201326. https:\/\/doi.org\/10.1038\/nrneph.2016.170.","journal-title":"Nat Rev Nephrol"},{"key":"817_CR26","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S)\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","DOI":"10.1016\/j.kint.2022.06.008"},{"issue":"7","key":"817_CR27","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1111\/dom.16385","volume":"27","author":"DV O\u2019Hara","year":"2025","unstructured":"O\u2019Hara DV, Jardine MJ. a review of the safety of sodium-glucose Co-transporter-2 inhibitors. Diabetes Obes Metab. 2025;27(7):3598\u2013606. https:\/\/doi.org\/10.1111\/dom.16385.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"817_CR28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/pds.5496","volume":"31","author":"CM Lewellyan","year":"2022","unstructured":"Lewellyan CM, Spoutz P, Schaefer M, Patterson ME. Risk of volume depletion events with concomitant use of sodium glucose co-transporter 2 inhibitors and loop diuretics: a self-controlled case series study. Pharmacoepidemiol Drug Saf. 2022;31(10):1102\u20139. https:\/\/doi.org\/10.1002\/pds.5496.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"13","key":"817_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.jacc.2024.06.002","volume":"84","author":"SM Hollenberg","year":"2024","unstructured":"Hollenberg SM, Stevenson LW, Ahmad T, Bozkurt B, Butler J, Davis LL, et al. 2024 ACC expert consensus decision pathway on clinical assessment, management, and trajectory of patients hospitalized with heart failure focused update: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2024;84(13):1241\u201367. https:\/\/doi.org\/10.1016\/j.jacc.2024.06.002.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"817_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-019-0899-9","volume":"18","author":"D Giugliano","year":"2019","unstructured":"Giugliano D, Esposito K. Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovasc Diabetol. 2019;18(1):94. https:\/\/doi.org\/10.1186\/s12933-019-0899-9.","journal-title":"Cardiovasc Diabetol"},{"issue":"10285","key":"817_CR31","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"K Rahimi","year":"2021","unstructured":"Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Ramakrishnan R, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625\u201336. https:\/\/doi.org\/10.1016\/S0140-6736(21)00590-0.","journal-title":"Lancet"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00817-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-026-00817-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-026-00817-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:38:51Z","timestamp":1785515931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-026-00817-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":31,"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1007\/s40292-026-00817-1","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this meta-analysis. The study received no funding.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This meta-analysis was conducted on study-level data from publicly available clinical trials. Hence, approval from the ethics committee was not required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}